Real solutions for real world problems.
Developing a new drug costs around $2.6 billion1, but once it’s in the market 31% of patients do not fill their prescriptions2, and then, just half of patients take their drugs correctly3.
Increasing adherence by just 10% could not only improve outcomes, it could represent a $124 billion revenue opportunity for biopharma.4
Whether it’s personalized patient engagement analytics, market intelligence on drug and device usage, or building blocks for patient-facing apps, our BrightInsight Platform offers comprehensive solutions that can improve patient adherence.
Put real-world data to work.
The biopharma industry faces escalating pressure on pricing transparency and reimbursement.
By integrating drug and device data from multiple sources, while working seamlessly with existing EMR and other IT systems, our BrightInsight Platform provides compelling analytics that can demonstrate improved outcomes.